Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes

Metabolism: Clinical and Experimental

Volumn 51, Issue 3, 2002, Pages 334-342

  Pontrelli, Louisa ^a,b   Parris, Wendy ^a,b   Adeli, Khosrow ^a,b   Cheung, Raphael C ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF WINDSOR   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; ATORVASTATIN; C PEPTIDE; CHOLESTEROL; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ARTICLE; ATHEROGENESIS; CLASSIFICATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DENSITY; DIET RESTRICTION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EXPOSURE; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HUMAN; HYPOLIPEMIA; LIPOPROTEIN BLOOD LEVEL; METABOLIC PARAMETERS; MOLECULAR WEIGHT; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN DEGRADATION; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; STATISTICAL SIGNIFICANCE;

EID: 0036119959     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2002.30510     Document Type: Article

References (39)

1. Diabetes: Statins, fibrates, or both?
2. Status report of lipid-lowering trials in diabetes
3. Ciprofibrate effects on carbohydrate and lipid metabolism in type 2 diabetes mellitus subjects
4. Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators
5. Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia
6. Atorvastatin for the management of type 2 diabetic patients with dyslipidaemia. A mid-term (9 months) treatment experience
7. A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia
8. Statins: Effective antiatherosclerotic therapy
9. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia
10. Therapeutic modulation of low-density lipoprotein size
11. Diabetic dyslipidemia
12. Current perspectives on statins
13. Choosing drug therapy for patients with hyperlipidemia
14. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: Subgroup analyses in the Scandinavian Simvastatin Survival Study
15. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators
16. Regulated intracellular degradation of apolipoprotein B in semipermeable HepG2 cells
17. Studies on intracellular translocation of apolipoprotein B in a permeabilized HepG2 system
18. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
19. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man
20. Identification of multiple subclasses of plasma low density lipoproteins in normal humans
21. Nondenaturing polyacrylamide gradient gel electrophoresis
22. Relationship of intermediate and low-density lipoprotein subspecies to risk of coronary artery disease
23. Predominance of large LDL and reduced HDL2 cholesterol in normolipidemic men with coronary artery disease
24. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients
25. Treating patients with documented atherosclerosis to National Cholesterol Education Program - Recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin
26. The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: Results of a randomized, double-masked study
27. Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study
28. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: Studies in subjects with various degrees of glucose tolerance and insulin sensitivity
29. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability
30. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease
31. Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern
32. Pravastatin treatment in combined hyperlipidaemia. Effect on plasma lipoprotein levels and size
33. Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans
34. Action of atorvastatin in combined hyperlipidemia: Preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles
35. Choice of lipid-regulating drugs
36. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
37. Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells
38. Intracellular degradation of apolipoprotein B generates an N-terminal 70 kDa fragment in the endoplasmic reticulum
39. Translocation of apolipoprotein B across the endoplasmic reticulum is blocked in abetalipoproteinemia